Valgen has applied for more than 600 patents worldwide for fundamental principles, core solutions, and/or key innovations of its products of which 200 of the patents have been granted. Four of its products have passed NMPA's special review for innovative medical devices, and five of its products have been officially marketed. On November 22, 2023, the company and Venus Medtech reached an exclusive strategic marketing cooperation intention in relation to the DragonFly™ Transcatheter Mitral Valve Repair System.
Cyborg Score Rationale
Valgen demonstrates solid innovation credentials with 600+ patent applications, regulatory approvals in China, and strategic partnerships with established players like Venus Medtech. However, as a private company operating primarily in China with limited international presence, it faces geographic constraints and regulatory concentration risk.
Top Insights
DragonFly Transcatheter Mitral Valve Repair System was approved by China's National Medical Products Administration in November 2023
Valgen Medtech is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups
Valgen Medtech has employed more than 280 researchers, medical specialists, technicians, and manufacturing workers throughout China, nearly 20% of which are high-end talents with master's or doctoral degrees
Valgen Medtech is headquartered in Hangzhou High-Tech Zone (Binjiang) Hangzhou and established an R&D center in Shenzhen
Named Competitors
MitraClip — Transcatheter mitral valve repair system
TAVR Systems — Transcatheter aortic valve replacement